Abstract C081: Discovery and characterization of AKT1-E17K mutant-selective inhibitors for the treatment of AKT1-E17K mutant cancers

Tine Wyseure(Scripps Research Institute), Matt Patricelli(Vividion Therapeutics (United States)), Fabian T. Goericke(Vividion Therapeutics (United States)), Brian N. Cook(Vividion Therapeutics (United States)), Noah Ibrahim(Vividion Therapeutics (United States)), Todd M. Kinsella(Vividion Therapeutics (United States)), Shota Kikuchi(Vividion Therapeutics (United States)), Rediet Zewdu(Huntsman (United States)), Sarah N. Ur(Vividion Therapeutics (United States)), Tomas Vilimas(Frederick National Laboratory for Cancer Research), David S. Weinstein(National Bureau of Economic Research), Blake Houser(Vividion Therapeutics (United States)), Gabe Simon(Vividion Therapeutics (United States)), Albert E. Parker(Montana State University), Marie Pariollaud(Scripps Research Institute), Debarati Mukherjee(Vividion Therapeutics (United States)), Jonathan Pollock(Vividion Therapeutics (United States)), Joseph McLaughlin(Vividion Therapeutics (United States)), Zoe Rush(Vividion Therapeutics (United States)), Betty Lam(Vividion Therapeutics (United States)), Nil Roy(Vividion Therapeutics (United States)), J. Sigler(Vividion Therapeutics (United States)), BENJAMIN HORNING(Vividion Therapeutics (United States)), Sarah Jacinto(Vividion Therapeutics (United States)), Alanna Sedgwick(Vividion Therapeutics (United States))

Molecular Cancer Therapeutics

October 22, 2025

Cited by 0

|JAMA Oncology|2015|834

|Nature Medicine|2014|463

|Journal of Clinical Investigation|2018|208

|Cancer Discovery|2020|91

|Nature Methods|2018|87

Related Papers